Ibuzatrelvir - Pfizer
Alternative Names: PF-07817883Latest Information Update: 21 Jul 2025
At a glance
- Originator Pfizer
- Class Antivirals; Carbamates; Fluorocarbons; Pyrrolidines; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 10 Jul 2025 Phase-III clinical trials in COVID-2019 infections (Combination therapy) in Japan, USA (PO) (NCT07013474) (EUCT-2024-517671-21-00)
- 10 Jul 2025 Phase-III clinical trials in COVID-2019 infections (Monotherapy) in Japan, USA (PO) (NCT07013474) (EUCT-2024-517671-21-00)
- 10 Jun 2025 Pfizer plans a phase III trial for COVID-2019 infections (Combination therapy) in USA and Japan (PO, Tablet) in July 2025 (NCT07013474)